Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)

BACKGROUND: Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2–29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. METHODS: In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Rui, Chen, Zhihai, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223615/
https://www.ncbi.nlm.nih.gov/pubmed/31673977
http://dx.doi.org/10.1007/s15010-019-01364-9
_version_ 1783533772354879488
author Song, Rui
Chen, Zhihai
Li, Wei
author_facet Song, Rui
Chen, Zhihai
Li, Wei
author_sort Song, Rui
collection PubMed
description BACKGROUND: Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2–29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. METHODS: In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. RESULTS: Patients had a sustainable virologic, immunologic and symptomatic recovery. CONCLUSIONS: Favipiravir may be a prosiming drug for the treatment of SFTS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s15010-019-01364-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7223615
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72236152020-05-15 Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705) Song, Rui Chen, Zhihai Li, Wei Infection Case Report BACKGROUND: Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2–29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. METHODS: In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. RESULTS: Patients had a sustainable virologic, immunologic and symptomatic recovery. CONCLUSIONS: Favipiravir may be a prosiming drug for the treatment of SFTS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s15010-019-01364-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-10-31 2020 /pmc/articles/PMC7223615/ /pubmed/31673977 http://dx.doi.org/10.1007/s15010-019-01364-9 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2019 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Song, Rui
Chen, Zhihai
Li, Wei
Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title_full Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title_fullStr Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title_full_unstemmed Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title_short Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)
title_sort severe fever with thrombocytopenia syndrome (sfts) treated with a novel antiviral medication, favipiravir (t-705)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223615/
https://www.ncbi.nlm.nih.gov/pubmed/31673977
http://dx.doi.org/10.1007/s15010-019-01364-9
work_keys_str_mv AT songrui severefeverwiththrombocytopeniasyndromesftstreatedwithanovelantiviralmedicationfavipiravirt705
AT chenzhihai severefeverwiththrombocytopeniasyndromesftstreatedwithanovelantiviralmedicationfavipiravirt705
AT liwei severefeverwiththrombocytopeniasyndromesftstreatedwithanovelantiviralmedicationfavipiravirt705

Ejemplares similares